Page last updated: 2024-11-08
9-mercaptodethiobiotin
Description
9-mercaptodethiobiotin: structure given in first source; intermediate in biotin biosynthesis [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
9-mercaptodethiobiotin : A member of the class of imidazolidinones that is dethiobiotin carrying a mercapto substituent at position 9. An intermediate in the biosynthesis of biotin. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]
Cross-References
Synonyms (10)
| Synonym |
|---|
| 9-mercaptodethiobiotin |
| 9-mercaptodesthiobiotin |
| 6-[(4r,5r)-2-oxo-5-(sulfanylmethyl)imidazolidin-4-yl]hexanoic acid |
| 139936-57-5 |
| CHEBI:133388 |
| 830346-98-0 |
| rel-6-((4r,5r)-5-(mercaptomethyl)-2-oxoimidazolidin-4-yl)hexanoic acid |
| DTXSID30930664 |
| 6-[2-hydroxy-5-(sulfanylmethyl)-4,5-dihydro-1h-imidazol-4-yl]hexanoic acid |
| 6-((4r,5r)-5-(mercaptomethyl)-2-oxoimidazolidin-4-yl)hexanoic acid |
Roles (1)
| Role | Description |
|---|
| Escherichia coli metabolite | Any bacterial metabolite produced during a metabolic reaction in Escherichia coli. |
| [role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] |
Drug Classes (4)
| Class | Description |
|---|
| monocarboxylic acid | An oxoacid containing a single carboxy group. |
| ureas | |
| imidazolidinone | An imidazolidine containing one or more oxo groups. |
| thiol | An organosulfur compound in which a thiol group, -SH, is attached to a carbon atom of any aliphatic or aromatic moiety. |
| [compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] |
Research
Studies (6)
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (16.67) | 18.2507 |
| 2000's | 2 (33.33) | 29.6817 |
| 2010's | 3 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |
Market Indicators
Research Demand Index: 12.82
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
| Metric | This Compound (vs All) |
|---|
| Research Demand Index | 12.82 (24.57) | | Research Supply Index | 1.95 (2.92) | | Research Growth Index | 4.77 (4.65) | | Search Engine Demand Index | 0.00 (26.88) | | Search Engine Supply Index | 0.00 (0.95) |
| |
Study Types
| Publication Type | This drug (%) | All Drugs (%) |
|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 0 (0.00%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 6 (100.00%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |